Cargando…
Development of pyogenic granuloma with strong vascular endothelial growth factor receptor-2 expression during ramucirumab treatment
The angiogenesis inhibitor ramucirumab (IMC-1121B) is a fully humanised IgG1 monoclonal antibody targeting the extracellular domain of vascular endothelial growth factor receptor 2. Ramucirumab has been approved as a second-line treatment for lung cancer. Pyogenic granuloma is an acquired, benign va...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6887457/ https://www.ncbi.nlm.nih.gov/pubmed/31776151 http://dx.doi.org/10.1136/bcr-2019-231464 |
_version_ | 1783475034894893056 |
---|---|
author | Ibe, Tatsuya Hamamoto, Yoichiro Takabatake, Mikage Kamoshida, Shingo |
author_facet | Ibe, Tatsuya Hamamoto, Yoichiro Takabatake, Mikage Kamoshida, Shingo |
author_sort | Ibe, Tatsuya |
collection | PubMed |
description | The angiogenesis inhibitor ramucirumab (IMC-1121B) is a fully humanised IgG1 monoclonal antibody targeting the extracellular domain of vascular endothelial growth factor receptor 2. Ramucirumab has been approved as a second-line treatment for lung cancer. Pyogenic granuloma is an acquired, benign vascular tumour of the skin or mucous membrane. We encountered a patient with pyogenic granuloma who was treated with ramucirumab. The patient was a 48-year-old Japanese woman with advanced lung cancer who had been heavily pretreated using several lines of chemotherapy. Ramucirumab was administered as the fifth-line treatment with docetaxel. After 10 days, a painless rice-coloured or pink papule appeared on her finger. One month later, it increased in size to 20 mm. We examined the pathological condition by immunostaining using the resected specimen diagnosed as pyogenic granuloma. Paradoxically, this vascular tumour arose during the administration of an angiogenesis inhibitor. |
format | Online Article Text |
id | pubmed-6887457 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-68874572019-12-04 Development of pyogenic granuloma with strong vascular endothelial growth factor receptor-2 expression during ramucirumab treatment Ibe, Tatsuya Hamamoto, Yoichiro Takabatake, Mikage Kamoshida, Shingo BMJ Case Rep Findings That Shed New Light on the Possible Pathogenesis of a Disease or an Adverse Effect The angiogenesis inhibitor ramucirumab (IMC-1121B) is a fully humanised IgG1 monoclonal antibody targeting the extracellular domain of vascular endothelial growth factor receptor 2. Ramucirumab has been approved as a second-line treatment for lung cancer. Pyogenic granuloma is an acquired, benign vascular tumour of the skin or mucous membrane. We encountered a patient with pyogenic granuloma who was treated with ramucirumab. The patient was a 48-year-old Japanese woman with advanced lung cancer who had been heavily pretreated using several lines of chemotherapy. Ramucirumab was administered as the fifth-line treatment with docetaxel. After 10 days, a painless rice-coloured or pink papule appeared on her finger. One month later, it increased in size to 20 mm. We examined the pathological condition by immunostaining using the resected specimen diagnosed as pyogenic granuloma. Paradoxically, this vascular tumour arose during the administration of an angiogenesis inhibitor. BMJ Publishing Group 2019-11-26 /pmc/articles/PMC6887457/ /pubmed/31776151 http://dx.doi.org/10.1136/bcr-2019-231464 Text en © BMJ Publishing Group Limited 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Findings That Shed New Light on the Possible Pathogenesis of a Disease or an Adverse Effect Ibe, Tatsuya Hamamoto, Yoichiro Takabatake, Mikage Kamoshida, Shingo Development of pyogenic granuloma with strong vascular endothelial growth factor receptor-2 expression during ramucirumab treatment |
title | Development of pyogenic granuloma with strong vascular endothelial growth factor receptor-2 expression during ramucirumab treatment |
title_full | Development of pyogenic granuloma with strong vascular endothelial growth factor receptor-2 expression during ramucirumab treatment |
title_fullStr | Development of pyogenic granuloma with strong vascular endothelial growth factor receptor-2 expression during ramucirumab treatment |
title_full_unstemmed | Development of pyogenic granuloma with strong vascular endothelial growth factor receptor-2 expression during ramucirumab treatment |
title_short | Development of pyogenic granuloma with strong vascular endothelial growth factor receptor-2 expression during ramucirumab treatment |
title_sort | development of pyogenic granuloma with strong vascular endothelial growth factor receptor-2 expression during ramucirumab treatment |
topic | Findings That Shed New Light on the Possible Pathogenesis of a Disease or an Adverse Effect |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6887457/ https://www.ncbi.nlm.nih.gov/pubmed/31776151 http://dx.doi.org/10.1136/bcr-2019-231464 |
work_keys_str_mv | AT ibetatsuya developmentofpyogenicgranulomawithstrongvascularendothelialgrowthfactorreceptor2expressionduringramucirumabtreatment AT hamamotoyoichiro developmentofpyogenicgranulomawithstrongvascularendothelialgrowthfactorreceptor2expressionduringramucirumabtreatment AT takabatakemikage developmentofpyogenicgranulomawithstrongvascularendothelialgrowthfactorreceptor2expressionduringramucirumabtreatment AT kamoshidashingo developmentofpyogenicgranulomawithstrongvascularendothelialgrowthfactorreceptor2expressionduringramucirumabtreatment |